TORONTO, Aug. 27 /CNW/ - IntelliPharmaCeutics Ltd. (Delaware) is pleased
to announce that its operating company IntelliPharmaCeutics Corp. of Toronto
has received a letter from the Food and Drug Administration (FDA) of the
United States indicating that its abbreviated new drug application (ANDA)
submitted pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic
Act with the FDA for approval to sell a certain drug product commercially in
the United States was accepted for filing as of the filing date of May 14,
2007.
